Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

Abstract:

:Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripheral blood and lymphoid organs. CDX-301 has an identical amino-acid sequence and comparable biological activity to the previously tested rhuFlt3L, which ceased clinical development over a decade ago. This Phase 1 trial assessed the safety, pharmacokinetic, pharmacodynamic and immunologic profile of CDX-301, explored alternate dosing regimens and examined the impact of rhuFlt3L on key immune cell subsets. Thirty healthy volunteers received CDX-301 (1-75 μg/kg/day) over 5-10 days. One event of Grade 3 community-acquired pneumonia occurred. There were no other infections, dose-limiting toxicities or serious adverse events. CDX-301 resulted in effective peripheral expansion of monocytes, hematopoietic stem and progenitor cells and key subsets of myeloid DCs and plasmacytoid DCs, with no clear effect on regulatory T cells. These data from healthy volunteers support the potential for CDX-301, as monotherapy or in combination with other agents, in various indications including allogeneic HSC transplantation and immunotherapy, but the effects of CDX-301 will need to be investigated in each of these patient populations.

journal_name

Bone Marrow Transplant

authors

Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

doi

10.1038/bmt.2015.74

subject

Has Abstract

pub_date

2015-07-01 00:00:00

pages

924-30

issue

7

eissn

0268-3369

issn

1476-5365

pii

bmt201574

journal_volume

50

pub_type

杂志文章
  • Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.

    abstract::The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is used to counsel patients regarding the risk of transplantation and selection of conditioning regimens. Pulmonary disease, most frequently demonstrated by a decreased diffusion capacity of carbon monoxide (DLCO), is the most prevalent comorbi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.31

    authors: Coffey DG,Pollyea DA,Myint H,Smith C,Gutman JA

    更新日期:2013-09-01 00:00:00

  • Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.

    abstract::At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a ch...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.186

    authors: Cacchione A,LeMaitre A,Couanet DV,Benhamou E,Amoroso L,Simonnard N,Hartmann O

    更新日期:2008-10-01 00:00:00

  • Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.

    abstract::Calcineurin inhibitor (CNI)-sparing T-cell depleted (TCD) hematopoietic stem cell transplants (HSCTs) are presumed to be less nephrotoxic than conventional HSCTs. We evaluated incidence and risk factors for kidney failure and chronic kidney disease (CKD) in 231 TCD and 212 conventional HSCT recipients. Kidney failure ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.343

    authors: Glezerman IG,Devlin S,Maloy M,Bui M,Jaimes EA,Giralt SA,Jakubowski AA

    更新日期:2017-05-01 00:00:00

  • Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.

    abstract::Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were mea...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705481

    authors: Hendriks MP,Blijlevens NM,Schattenberg AV,Burger DM,Donnelly JP

    更新日期:2006-10-01 00:00:00

  • High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB).

    abstract::A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.208

    authors: Benesch M,Bartelheim K,Fleischhack G,Gruhn B,Schlegel PG,Witt O,Stachel KD,Hauch H,Urban C,Quehenberger F,Massimino M,Pietsch T,Hasselblatt M,Giangaspero F,Kordes U,Schneppenheim R,Hauser P,Klingebiel T,Frühwald MC

    更新日期:2014-03-01 00:00:00

  • (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

    abstract::Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2010.339

    authors: Abou-Nassar KE,Stevenson KE,Antin JH,McDermott K,Ho VT,Cutler CS,LaCasce AS,Jacobsen ED,Fisher DC,Soiffer RJ,Alyea EP,Koreth J,Freedman AS

    更新日期:2011-12-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

    abstract::The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702069

    authors: Schriber J,Milk B,Shaw D,Christiansen N,Baer M,Slack J,Tezcan H,Wetzler M,Herzig G

    更新日期:1999-12-01 00:00:00

  • Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.

    abstract::Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.bmt.1705935

    authors: Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

    更新日期:2008-03-01 00:00:00

  • Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?

    abstract::The Cleveland Clinic blood and marrow transplant program has routinely performed 'backup' autologous harvests in unrelated recipients with hematological malignancies in remission, lymphoma without marrow involvement and CML in chronic phase. We reviewed all adult or cord unrelated donor (URD) transplants performed fro...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.95

    authors: Stotler C,Bolwell B,Sobecks R,Dean R,Serafino S,Rybicki L,Andresen S,Pohlman B,Kalaycio M,Copelan E

    更新日期:2010-01-01 00:00:00

  • Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.

    abstract::Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01065-0

    authors: Sugita J,Kamimura T,Ishikawa T,Ota S,Eto T,Kuroha T,Miyazaki Y,Kumagai H,Matsuo K,Akashi K,Taniguchi S,Harada M,Teshima T

    更新日期:2020-09-24 00:00:00

  • Osteopetrosis: a single centre experience of stem cell tranisplantation and prenatal diagnosis.

    abstract::Malignant osteopetrosis (MOP) is an autosomal recessive disease in which osteoclast dysfunction results in excessive bone deposition and early infant death. Thirteen children suffering from MOP from four related families all belonging to one Bedouin tribe, were studied. The disease was diagnosed as early as at a few d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702743

    authors: Kapelushnik J,Shalev C,Yaniv I,Aker M,Carmi R,Cohen Z,Mozer A,Schulman C,Stein G,Or R

    更新日期:2001-01-01 00:00:00

  • Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

    abstract::Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.364

    authors: Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

    更新日期:2017-06-01 00:00:00

  • What would Karl Landsteiner do? The ABO blood group and stem cell transplantation.

    abstract::ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705101

    authors: Heal JM,Liesveld JL,Phillips GL,Blumberg N

    更新日期:2005-11-01 00:00:00

  • First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (

    abstract::Thalidomide-dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line the...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究,收录出版

    doi:10.1038/sj.bmt.1705050

    authors: Abdelkefi A,Torjman L,Ben Romdhane N,Ladeb S,El Omri H,Ben Othman T,Elloumi M,Bellaj H,Lakhal A,Jeddi R,Aissaouï L,Saad A,Hsaïri M,Boukef K,Dellagi K,Ben Abdeladhim A

    更新日期:2005-08-01 00:00:00

  • Stem cell enumeration in cord blood vs bone marrow and peripheral blood.

    abstract::Recent reports have suggested that the total number of autologous or allogeneic hematopoietic stem cell (HSC) infused after high-dose chemotherapy might predict survival, post-transplant morbidity and rate of hematopoietic engraftment. However, HSC capable of long-term multilineage potential are still poorly defined, ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bertolini F,Battaglia M,Lanza A,Gibelli N,Palermo B,Pavesi L,Robustelli della Cuna G

    更新日期:1998-07-01 00:00:00

  • Diffuse alveolar hemorrhage following autologous bone marrow infusion.

    abstract::Autologous BMT performed in a 57-year-old woman with relapsed large cell lymphoma was complicated by two consecutive episodes of diffuse alveolar hemorrhage (DAH). The second episode occurred immediately after infusion of autologous BM. DAH is an increasingly recognized complication of autologous BMT and carries a hig...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Corso S,Vukelja SJ,Wiener D,Baker WJ

    更新日期:1993-09-01 00:00:00

  • Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).

    abstract::Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

    更新日期:1996-11-01 00:00:00

  • Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).

    abstract::Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700905

    authors: Oblon DJ,Paul S,Yankee R

    更新日期:1997-09-01 00:00:00

  • Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma.

    abstract::We describe a patient with longstanding steroid-dependent systemic lupus erythematosus (SLE) in whom clinical and serological remission was achieved following high-dose therapy and autologous bone marrow rescue for high-grade non-Hodgkin's lymphoma. However, 3 years later, autoimmune disease re-presented in the form o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700815

    authors: Snowden JA,Patton WN,O'Donnell JL,Hannah EE,Hart DN

    更新日期:1997-06-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract::An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701038

    authors: Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期:1998-01-01 00:00:00

  • Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies.

    abstract::Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703721

    authors: Chatterjee R,Kottaridis PD

    更新日期:2002-11-01 00:00:00

  • Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.

    abstract::Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

    更新日期:1994-06-01 00:00:00

  • Evaluation of oxidative and antioxidative parameters in pediatric hematopoietic SCT patients.

    abstract::Conditioning regimens preceding hematopoietic SCT (HSCT) usually consist of high-dose chemotherapy. Chemotherapy and radiation therapy are associated with increased formation of free radicals and depletion of critical plasma and tissue antioxidants. Oxidative stress and antioxidant depletion have been described during...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.145

    authors: Sabuncuoğlu S,Kuşkonmaz B,Uckun Çetinkaya D,Ozgüneş H

    更新日期:2012-05-01 00:00:00

  • Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.

    abstract::The purpose of this work was to determine the maximum tolerated (phase II) dose of melphalan and etoposide that can be given in conjunction with autologous BM re-infusion in patients who have refractory or relapsed solid tumors. Twenty-six patients with refractory or relapsed breast cancer (n = 15), small cell lung ca...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Lazarus HM,Gray R,Ciobanu N,Winter J,Weiner RS

    更新日期:1994-09-01 00:00:00

  • Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

    abstract::In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2013.68

    authors: Tanaka J,Kanamori H,Nishiwaki S,Ohashi K,Taniguchi S,Eto T,Nakamae H,Minagawa K,Miyamura K,Sakamaki H,Morishima Y,Kato K,Suzuki R,Nishimoto N,Oba K,Masauzi N

    更新日期:2013-11-01 00:00:00

  • A risk-adapted approach to acute GVHD treatment: are we there yet?

    abstract::Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.261

    authors: Holtan SG,MacMillan ML

    更新日期:2016-02-01 00:00:00

  • Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.

    abstract::To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

    更新日期:1988-01-01 00:00:00

  • Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.

    abstract::Persistent thrombocytopenia and thrombotic complications are commonly observed in bone marrow transplant (BMT) patients. We describe two incidents following BMT in which heparin may have played a contributory role. One patient developed subclavian venous thrombosis following autologous BMT in spite of the severe throm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tezcan AZ,Tezcan H,Gastineau DA,Armitage JO,Haire WD

    更新日期:1994-09-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract::Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期:1994-12-01 00:00:00